Abstract 13 Figure 2 Changes in key metabolites after period of CPAP

OSAHS, and could reflect the cardiometabolic risk associated with OSAHS better than current diagnostic modalities.

REFERENCE

1. O'Rourke, et al. Plasma metabolomics identifies OSAHS. ERS Congress 2021.

14

NON-INTERVENTIONAL, QUALITATIVE STUDY ASSESSING PATIENT PERSPECTIVES OF THE BURDEN OF EXCESSIVE DAYTIME SLEEPINESS IN OBSTRUCTIVE SLEEP APNOEA

¹Ginger S Carls*, ²Robin Pokrzywinski, ³Hayley Karn, ³Hannah Collacott, ⁴Sam Mettam. ¹Jazz Pharmaceuticals, Luxembourg, Luxembourg; ²Patient-Centered Research, Evidera, Bethesda, USA; ³Patient-Centered Research, Evidera, London, UK; ⁴Health Economics and Outcomes Research, Jazz Pharmaceuticals, Oxford, UK

10.1136/bmjresp-2021-bssconf.12

Introduction Many patients with obstructive sleep apnoea (OSA) experience excessive daytime sleepiness (EDS) despite primary airway therapy. This study aimed to understand the burden of EDS in European adults with OSA who received primary airway therapy.

Methods Non-interventional, qualitative study in patients with EDS in OSA, from the UK, Germany, and Spain. Post-IRB approval, patients with self-reported OSA were recruited via patient panels. Eligible patients had Epworth Sleepiness Scale (ESS) score ≥ 10 , self-reported adequate nightly sleep, current/past primary airway therapy, and no other self-reported EDS-associated conditions. Patients completed a quantitative pre-interview questionnaire and a qualitative, semi-structured telephone interview.

Results Fifteen patients (n=5/country; 60% female; mean age, 48.7 years; mean years since OSA diagnosis, 7.7) were included. Six of 8 current positive airway pressure (PAP) users were compliant (≥ 4 h, 7 nights/wk); 6 of 7 non-PAP users had prior airway surgery. Mean ESS score was 14.5; 60% of those without an EDS diagnosis reported discussing EDS with

their doctor. Patients experienced broadly consistent negative impacts from EDS, including physical functioning (n=15), daily life activities (n=15), work/study habits (n=14), emotional (n=15), social life (n=14), and cognition (n=13). No between-country differences were observed.

Discussion Findings demonstrate the patient-perceived burden of residual EDS in OSA. Forty percent of patients without an EDS diagnosis did not discuss EDS with their doctor despite daily impacts.

15

A REAL-WORLD STUDY ASSESSING THE RELATIONSHIP BETWEEN POSITIVE AIRWAY PRESSURE TREATMENT, EXCESSIVE DAYTIME SLEEPINESS, AND PATIENT SATISFACTION IN OBSTRUCTIVE SLEEP APNOEA

¹Sairam Parthasarathy*, ²Danielle Hyman, ³James Doherty, ³Ragy Saad, ³Jerry Zhang, ²Susan Morris, ⁴Lev Eldemir, ⁵Benjamin Fox, ⁵Mai Ka Ying Vang, ⁵Jessica Schroeder, ⁵Nell J Marshall, ³Gregory Parks. ¹University of Arizona, Tucson, USA; ²Formerly of Jazz Pharmaceuticals, Palo Alto, USA; ³Jazz Pharmaceuticals, Palo Alto, USA; ⁴Formerly of Evidation Health, San Mateo, USA; ⁵Evidation Health, San Mateo, USA

10.1136/bmjresp-2021-bssconf.13

Introduction Excessive daytime sleepiness (EDS) persists in some positive airway pressure (PAP)-treated patients with obstructive sleep apnoea (OSA). This study examined prevalence and severity of EDS in a real-world population with OSA to understand how EDS, PAP adherence, and patient satisfaction with care relate.

Methods US-resident adults (self-reported clinician OSA diagnosis [1/1/2015-31/3/2020]) were surveyed (Epworth Sleepiness Scale [ESS], PAP usage, and patient satisfaction) in Evidation Health's Achievement app. Self-reported PAP use was categorised: nonuse, nonadherent (<4 h/night or <5 d/wk), intermediate ($4-6$ h/night, ≥ 5 d/wk), or highly adherent (≥ 6 h/night, ≥ 5 d/wk). ESS > 10 defined EDS. In PAP users, a linear model tested whether PAP use and ESS score relate; logistic regression models tested how PAP use (nonadherence=0,

adherence=1) and EDS impact satisfaction with healthcare providers (HCPs) and overall OSA care. Due to no adjustments for multiplicity, P-values are nominal.

Results Of 2289 participants (50.3% female; mean±SD 44.8 ±11.1 years old; 42.5% ESS>10), 72% were satisfied with HCPs and 65% with OSA care. In the nonuse (n=700), non-adherent (n=153), intermediate (n=225), and highly adherent (n=1211) groups, 47%, 52%, 53%, and 36% had EDS, respectively. An additional h/night PAP use was associated with lower ESS scores (n=1589, $\beta=-0.28$; 95% confidence interval [CI]=-0.40, -0.16; $P<0.001$). In PAP users (n=1589), adherence associated with higher satisfaction with HCPs (adjusted odds ratio [adjOR]=2.37; 95% CI=1.64, 3.43; $P<0.001$) and OSA care (adjOR=2.91; 95% CI=2.03, 4.17; $P<0.001$), and EDS with less satisfaction with HCPs (adjOR=0.62; 95% CI=0.48, 0.80; $P<0.001$) and OSA care (adjOR=0.50; 95% CI=0.39, 0.64; $P<0.001$).

Discussion In this real-world study, EDS was prevalent among highly adherent PAP users. PAP adherence was associated with greater patient satisfaction with HCPs and overall care, whereas persistent EDS was associated with lower patient satisfaction with HCPs and overall OSA care.

16 HOW CAN HEALTH COACHING IMPROVE COMPLIANCE IN CPAP PATIENTS AND DOES IT WORK?

Punam Korat*. Cardiff and Vale NHS Health Board, Cardiff, UK

10.1136/bmjresp-2021-bssconf.14

Introduction Health coaching/patient initiation is part of the NHS long term plan. This case study will look at the way health coaching can help in improving compliance and way we can implement it in our service.

Case Study 62yr old female who was set up on CPAP due to severe OSA. Had been compliant at the beginning from Average hours of 6.5hrs, AHI 2.3/hr when using CPAP and a mask leak of 0.5%, but then compliance had dropped. Patient seemed to have been struggling with mask fit and therefore was issued with several different masks.

Came into a compliance clinic and still using CPAP sporadically and no improvement in compliance. Coaching conversation started and patient then began explaining the main reasons which were stopping her from using her CPAP. Goals were set for the patient to achieve before her next appointment.

Method Initiating the coaching conversation did improve the patients compliance and she began feeling the benefits of her treatment and felt more positive towards it.

Conclusion Need to start having conversations and asking key questions to consistent non-compliant patients which may uncover the root cause and engaging the patient to take

control of their therapy and getting patients to find their own answers.

17 A SYSTEMATIC REVIEW OF THE TREATMENT OF RESTLESS LEG SYNDROME AND PERIODIC LIMB MOVEMENTS IN PEOPLE WITH SPINAL CORD INJURY

^{1,2}Susan (sue) Cross*, ³Nicola Barclay. ¹National Spinal Injuries Centre, Stoke Mandeville, Bucks. England., Aylesbury, UK; ²MSc Sleep Medicine graduate, Sleep and Circadian Neuroscience Institute, Dept. of Clinical Neurosciences, University of Oxford, UK; ³Supervising tutor, Sleep and Circadian Neuroscience Institute, Dept. of Clinical Neurosciences, University of Oxford, UK

10.1136/bmjresp-2021-bssconf.15

Introduction People with spinal cord injury (SCI) have a high prevalence of sleep disorders, which often remain undiagnosed and untreated, resulting in reduced quality of life. Their sleep may be disturbed by pain and spasms, but these could also be symptoms of Restless Leg Syndrome (RLS) or Periodic Limb Movements (PLMs). Studies estimate that RLS affects 17-19% of people with SCI. Little is known about the management of RLS or PLMs after SCI.

Method A systematic review was conducted following PRISMA guidelines, searching 5 databases, for studies of any intervention to manage RLS and/or PLMs in people with SCI. Outcomes of interest were changes in severity of RLS or PLMs, or effects on sleep quality (see table 1).

Results 465 Manuscripts were identified. 12 studies fulfilled inclusion/exclusion criteria, totalling 108 participants. Risk of bias assessment revealed low evidence quality due to small sample sizes and lack of randomised controlled trials.

Interventions investigated included • L-dopa and pramipexole were shown to reduce PLMs objectively measured by polysomnography, and subjectively reported RLS symptoms.

• Exercise reduced the PLM index measured by polysomnography.

• Intrathecal baclofen injection reduced PLMs.

Discussion It is thought that in people with SCI dopaminergic medications exert their effect in the spinal cord rather than in the brain.

Reviewed papers report potential confusion between PLMs and spasticity, and between neuropathic pain and RLS.

The RLS diagnostic criteria are challenging to apply after SCI. It is unclear how a patient with altered sensation following SCI will experience the 'urge' to move.

Conclusions There is evidence that some sleep measures improved with dopaminergic medication or exercise. Clinicians should consider investigation for RLS and PLMs in patients with neuropathic pain or spasticity unresponsive to usual treatment, with symptoms predominating in the evening or at night. These patients may respond to treatment for these sleep disorders.

Abstract 17 Table 1 Terms used in healthcare databases advanced search' (HDAS) function in OpenAthens

spinal cord injur* or spinal injur* or SCI or tetraplegia or quadriplegia or paraplegia
AND
periodic limb movement* or PLM or PLMS or PLMD or restless leg or RLS or Willis-Ekbom Disease